Acrivon Therapeutics Reports $17.964 Million Net Loss in Q2 2026, Decreasing from Previous Year

Acrivon Therapeutics, Inc. reported a net loss of $17.964 million for the second quarter of 2026, a decrease from the $21.006 million loss recorded in the same period of the previous year. For the first half of 2026, the company’s net loss was $37.006 million, down from $40.686 million in the first half of 2025. The reduction in losses is attributed to a decrease in operating expenses, which totaled $18.668 million for the second quarter, compared to $22.649 million in the prior year. This decline was primarily driven by lower research and development costs, which fell to $13.844 million from $16.182 million, and a reduction in general and administrative expenses from $6.467 million to $4.824 million.

Acrivon’s total operating expenses for the first six months of 2026 were $38.570 million, down from $44.311 million in the same period of 2025. The company’s research and development expenses for the first half of 2026 were $29.010 million, a decrease from $31.596 million in the previous year. The company noted that the decrease in research and development costs was primarily due to milestone achievements in 2025 that did not recur in 2026, as well as a reduction in costs associated with the ACR-2316 clinical trial.

In terms of financial position, Acrivon reported total assets of $99.092 million as of June 30, 2026, down from $129.717 million at the end of 2025. The company’s cash and cash equivalents were $41.417 million, slightly down from $41.499 million at the end of the previous fiscal year. Acrivon’s accumulated deficit increased to $311.887 million as of June 30, 2026, compared to $274.881 million at the end of 2025. The company has not generated any revenue to date and continues to rely on funding from equity offerings and other financing activities to support its operations.

Strategically, Acrivon is advancing its clinical pipeline, which includes ACR-368, a precision oncology asset currently in a Phase 2b trial for endometrial cancer, and ACR-2316, which is in a Phase 1/2 study for various solid tumors. The company has received Fast Track designation from the FDA for ACR-368 and is leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to enhance drug development. Acrivon anticipates that its existing cash and investments will be sufficient to fund operations into the fourth quarter of 2027, but acknowledges the need for additional funding to support ongoing and future development activities.

Looking ahead, Acrivon expects to continue incurring significant operating losses as it advances its drug candidates through clinical development. The company plans to maintain its focus on research and development while exploring opportunities for additional funding to support its growth strategy. Acrivon’s ability to raise capital will be critical to its future operations, particularly as it seeks to commercialize its drug candidates and expand its clinical programs.